相关临床试验
195
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1970
进行中（未招募）
3
1.5%
已完成
125
64.1%
招募中
1
0.5%
终止
36
18.5%
Unknown
19
9.7%
撤回
11
5.6%
暂无批准数据
• Dr. Carol Aghajanian has made significant contributions to gynecologic oncology through groundbreaking research in PARP inhibitors and immunotherapy combinations, revolutionizing treatment standards for ovarian and endometrial cancers. • As chief of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center, she has fostered a culture of mentorship and collaborative research, emphasizing the importance of patient-centered care in advancing scientific discoveries. • Her leadership in major clinical trials, including ARIEL3 and NRG-GY018/KEYNOTE-868, has led to new standard-of-care treatments, particularly in maintenance therapy and immunotherapy combinations for gynecologic cancers.
- A recent study reveals significant geographic disparities in the availability of gynecologic cancer clinical trials across the U.S. - States with higher economic vulnerability, as measured by FEMA's expected annual loss, have fewer gynecologic cancer trials per capita. - States with larger minoritized populations also show reduced access to these trials, highlighting potential inequities in healthcare access. - The findings underscore the need for targeted efforts to improve trial availability in underserved areas to ensure equitable access.
